The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SOHO 2024 | Advice for monitoring patients with different subtypes of T-cell lymphoma
Stefan Barta, MD, MS, University of Pennsylvania, Philadelphia, PA, emphasizes how aggressive nodal T-cell lymphomas should be monitored with regular scans to assess initial treatment response, and physical examinations after stem cell transplantation on a case-to-case basis. Dr Barta states that less aggressive forms should be monitored through regular physical assessments and evaluating patient-reported symptoms. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
